Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD and Prolonged Exposure for PTSD
NCT05132699Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Cannabidiol (CBD) with Placebo (2 arms). Primary endpoints: Clinician Administered PTSD Scale at 45 days and Posttraumatic Stress Disorder Checklist at 45 days. Started Apr 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05132699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132699.